drugset / Trial / NCT00657774

A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands

NCT00657774

Phase 1 Completed 160 enrolled SkyePharma AG Abbott · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The medications being used in this study are individually approved by the Food and Drug Administration (FDA). The medication under investigation is a combination of the two medications in one inhaler. The purpose of the study is to determine how the medication affects the amount, if any, of cortisol produced by the adrenal glands.

Timeline

Start
2008-04
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 100 ug Inhaled
Subject Fluticasone propionate Other / unclassified 250 ug Inhaled
Subject Formoterol Other / unclassified 10 ug Inhaled
Comparator Prednisone Other / unclassified 10 mg Oral

Indications